Evidence map›Paper›PMID 39715901›Full record

ArticleNature biomedical engineering2024

Leucine zipper-based immunomagnetic purification of CAR T cells displaying multiple receptors.

Scott E James, Sophia Chen, Brandon D Ng, Jacob S Fischman, Lorenz Jahn, Alexander P Boardman, Adhithi Rajagopalan, Harold K Elias, Alyssa Massa, Dylan Manuele and 16 more

Abstract read
In one paragraph

Article in Nature biomedical engineering, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. FOXP1 Knockdown Reprograms Th9 CAR-T Cells to Overcome Antigen Escape.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Adoptive transfer of VSIG4Journal of translational medicine · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Scott E JamesAdult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. scjames@coh.org.ORCID http://orcid.org/0000-0002-3601-6819
Sophia Chen *Department of Immunology, Sloan Kettering Institute, New York, NY, USA.
Brandon D Ng *Weill Cornell Medical College, New York, NY, USA.
Jacob S FischmanDepartment of Immunology, Sloan Kettering Institute, New York, NY, USA.
Lorenz JahnDepartment of Immunology, Sloan Kettering Institute, New York, NY, USA.ORCID http://orcid.org/0000-0002-9880-7026
Alexander P BoardmanLymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-7169-9275
Adhithi RajagopalanDepartment of Immunology, Sloan Kettering Institute, New York, NY, USA.
Harold K EliasDepartment of Immunology, Sloan Kettering Institute, New York, NY, USA.
Alyssa MassaDepartment of Immunology, Sloan Kettering Institute, New York, NY, USA.
Dylan ManueleDepartment of Immunology, Sloan Kettering Institute, New York, NY, USA.
Katherine B NicholsDepartment of Immunology, Sloan Kettering Institute, New York, NY, USA.ORCID http://orcid.org/0000-0003-0817-1667
Amina LazrakDepartment of Immunology, Sloan Kettering Institute, New York, NY, USA.
Nicole LeeDepartment of Immunology, Sloan Kettering Institute, New York, NY, USA.
Aoife M RocheDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Alexander G McFarlandDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Angelina PetrichenkoDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
John K EverettDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Frederic D BushmanDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-4740-4056
Teng FeiDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-7888-1715
Anastasia I KousaDepartment of Immunology, Sloan Kettering Institute, New York, NY, USA.
Andri L LemarquisDepartment of Immunology, Sloan Kettering Institute, New York, NY, USA.
Susan DeWolfLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jonathan U PeledAdult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-4029-7625
Santosha A VardhanaWeill Cornell Medical College, New York, NY, USA.
Christopher A KlebanoffWeill Cornell Medical College, New York, NY, USA.ORCID http://orcid.org/0000-0001-9645-3896
Marcel R M van den BrinkAdult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. mvandenbrink@coh.org.ORCID http://orcid.org/0000-0003-0696-4401

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Targeting Oncogenic Pathways in Genetically Complex SarcomasP50CA217694 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI William D. Tap · 2018 to 2026
$21.5M
The role of intestinal microbiota in graft-versus-host diseaseR01CA228308 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Philip L Lorenzi, Marcel R M van den Brink · 2018 to 2026
$5.2M
The role of autophagy gene Atg16L1 in allogeneic hematopoietic stem cell transplantation - Resubmission - 1R01HL123340 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CADWELL, KEN HASHIGIWA, VAN DEN BRINK, MARCEL R M · 2015 to 2022
$5.2M
The role of the intestinal microbiome in cancer immunotherapyR35CA284024 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Marcel R M van den Brink · 2023 to 2026
$4.2M
Molecular mechanisms of T cell responses to a clonal neoantigen resulting from a mutated driver oncogene.R37CA259177 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Christopher Austin Klebanoff · 2021 to 2026
$3.1M
Third-party “off the shelf” mature or precursor CAR T cells to prevent or treat malignant relapse after allo HCTR01HL147584 · NHLBI · SLOAN-KETTERING INST CAN RESEARCH · PI VAN DEN BRINK, MARCEL R M · 2019 to 2022
$2.7M
The role of intestinal microbiota in graft-versus-host diseaseR01CA228358 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI VAN DEN BRINK, MARCEL R M · 2018 to 2022
$2.6M
Novel cell therapy approaches for molecularly defined subsets of therapy-resistant melanomaR01CA286507 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Christopher Austin Klebanoff · 2023 to 2026
$1.8M
Multi-antigen-specific CAR T cells to treat acute myeloid leukemiaK08CA252157 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JAMES, SCOTT E · 2020 to 2024
$1.3M
Investigating altered T-cell metabolism during chronic antigen encounterK08CA237731 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI VARDHANA, SANTOSHA · 2020 to 2024
$1.3M
Understanding mechanisms of impaired immunity in the AML bone marrowK08CA293271 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Susan E DeWolf · 2024 to 2026
$911k
NCI NIH HHS K08 CA237731NCI NIH HHS K08 CA252157NCI NIH HHS K08 CA293271NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA217694NCI NIH HHS R01 CA286507NCI NIH HHS R35 CA284024NCI NIH HHS R37 CA259177NHLBI NIH HHS K08 HL143189NHLBI NIH HHS R01 HL147584U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) K08-CA252157U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01-CA228308U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01-CA228358U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01-HL123340U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01-HL147584
6 · The paper itself

Abstract

Resistance to chimaeric antigen receptor (CAR) T cell therapy develops through multiple mechanisms, most notably antigen loss and tumour-induced immune suppression. It has been suggested that T cells expressing multiple CARs may overcome the resistance of tumours and that T cells expressing receptors that switch inhibitory immune-checkpoint signals into costimulatory signals may enhance the activity of the T cells in the tumour microenvironment. However, engineering multiple features into a single T cell product is difficult because of the transgene-packaging constraints of current gene-delivery vectors. Here we describe a cell-sorting method that leverages leucine zippers for the selective single-step immunomagnetic purification of cells co-transduced with two vectors. Such 'Zip sorting' facilitated the generation of T cells simultaneously expressing up to four CARs and coexpressing up to three 'switch' receptors. In syngeneic mouse models, T cells with multiple CARs and multiple switch receptors eliminated antigenically heterogeneous populations of leukaemia cells coexpressing multiple inhibitory ligands. By combining diverse therapeutic strategies, Zip-sorted multi-CAR multi-switch-receptor T cells can overcome multiple mechanisms of CAR T cell resistance.

Indexed as

Immunomagnetic SeparationImmunotherapy, AdoptiveLeucine ZippersReceptors, Chimeric AntigenT-LymphocytesAnimalsCell Line, TumorHumansMiceReceptors, Antigen, T-CellReceptors, Antigen, T-CellReceptors, Chimeric Antigen

Identifiers

PMID39715901
PMCPMC11917073

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.